Improving Pain Therapeutics

Applying unique technologies to prolong and enhance efficacy, reduce adverse effects and increase patient’s comfort.

We are a clinical stage specialty pharmaceutical company
focused on the reformulation of established therapeutics

Our proprietary extended release drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while reducing the potential need for the use of opiates very often administered post surgically.

PRF - 110

Viscous clear oil-based solution that is instilled directly into the surgical wound

Providing localized and extended post-operative analgesia. Its physical characteristics and composition are key to it being well-tolerated and its ease of use.


The currently marketed non-opiate extended relief post-surgical topical products are based on a complicated formulation with either liposomes or an artificial polymer, and contain bupivacaine.

investors relation & media

Nasdaq: PRFX


CHANGE: -13.48%


LAST UPDATE: 05-26-2023 23:58

Send us a Message

this site made by